Effect of Timed-Restricted Eating on Metabolic Health

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)30 enrolled

Overview

We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.

Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obesity Non-Alcoholic Fatty Liver Disease Insulin Resistance

Interventions

Early time restricted eatingBEHAVIORAL

Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM

Late time restricted eatingBEHAVIORAL

Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM

Eligibility

Sex: ALLMin age: 50 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to provide informed consent; * BMI \> 30kg/m\^2; * Insulin resistance, as defined by fasting plasma insulin \> 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose \> 5.3 and \< 7.0 mmol/L; * Stable weight for 3 months prior to study inclusion * For women, 1 year after last menstrual cycle Exclusion Criteria: * Use of any medication, except for those related to treatment of metabolic syndrome; * Any medical condition interfering with study outcomes or design; * History of any psychiatric disorder, including eating disorders; * Performing shift work * Performing intensive sports (\>3 hours/week); * Smoking; * Drugs abuse or alcohol abuse (\>3 units/day); * Contraindication for MRI; * Known lactose/gluten intolerance; * Known soy, egg, milk or peanut allergy; * Childhood onset of obesity

Locations (1)

Amsterdam UMC, location AMC

Amsterdam, North Holland, Netherlands

RECRUITING

Outcomes

Primary Outcomes

Insulin Sensitivity

We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Secondary Outcomes

Change in plasma insulin

Fasted and stimulated insulin (pmol/L) will be measured during MMTT

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Change in plasma glucose

Fasted and stimulated glucose (mmol/L) will be measured during MMTT

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Change in intrahepatic fat

To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Change in beta cell function (C-peptide)

Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Change in insulin aignaling

Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)

Central Contacts

Jur Kroon, BSc

CONTACT

+31 683238752 jur.kroon@amsterdamumc.nl

Sarah E Siegelaar, MD PhD

CONTACT

s.e.siegelaar@amsterdamumc.nl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Change in glucose variability

In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.

Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

De novo lipogenesis

Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Immunological markers

We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Physical activity

Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.

Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

Functional brain activity

Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Food Craving

We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Eating behaviour

We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Hunger scale

We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Food addiction

We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Impulsiveness

We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Psychological factor - Chronotype

To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Subject experience with intervention

We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Delay discounting computational task

The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Iowa gambling computational task

We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.

Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2